Answers are grounded in this paper and cite their sources.
This study aimed to evaluate the current management of tinea capitis in the United States, specifically focusing on patients aged 0–2 months, 2 months to 2 years, and 2 years to 18 years. An online survey, distributed through the Pediatric Dermatology Research Alliance and the Society of Pediatric Dermatology, revealed the following preferences: fluconazole for those under 2 months, griseofulvin for those aged 2 months to 2 years, and terbinafine for those aged 2 years and older. There exists inter‐provider variation in tinea capitis treatment regimens within the pediatric dermatology community.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: